According to the Washington Post on the 10th (local time), multinational pharmaceutical companies such as Pfizer, Roche, Boehringer Ingelheim and Amgen are accelerating development to bring to market drugs that surpass Eli Lilly and Novo Nordisk's obesity treatments
Colan SD, Lipshultz SE, Lowe AM et al : Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry
Food supplements should not be used as a substitute for a varied and well-balanced diet
GLY-200 (oral pharmacologic duodenal exclusion drug) decreases appetite, increases satiation, and reduces food intake in patients with type 2 diabetes
Lab testing: Complete blood work (as required), including A1C and kidney and liver panels, to confirm eligibility and safe use